UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

Blood, 2012-11, Vol.120 (19), p.3958-3967

2012

Volltextzugriff (PDF)

Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Clinical cancer research, 2014-03, Vol.20 (6), p.1542-1554

2014

Volltextzugriff (PDF)

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

Clinical cancer research, 2011-12, Vol.17 (23), p.7313-7323

2011

Volltextzugriff (PDF)

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism

PloS one, 2015-12, Vol.10 (12), p.e0144825-e0144825

2015

Volltextzugriff (PDF)

The discovery of a reciprocal relationship between tyrosine-kinase signaling and cullin neddylation

PloS one, 2013-10, Vol.8 (10), p.e75200-e75200

2013

Volltextzugriff (PDF)

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

Clinical cancer research, 2016-01, Vol.22 (1), p.34-43

2016

Volltextzugriff (PDF)

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

Clinical cancer research, 2016-02, Vol.22 (4), p.847-857

2016

Volltextzugriff (PDF)

Cancer-Related Decision-Making Among Adolescents, Young Adults, Caregivers, and Oncology Providers

Qualitative health research, 2021-11, Vol.31 (13), p.2355-2363

2021

Volltextzugriff (PDF)

"Empathy without sympathy": An analysis of support-related preferences among young adult cancer survivors

Journal of psychosocial oncology, 2022-07, Vol.40 (4), p.457-472

2022

Volltextzugriff (PDF)

T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia

Molecular cancer therapeutics, 2023-09, Vol.22 (9), p.1040-1051

2023

Volltextzugriff (PDF)

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR

Blood, 2016-05, Vol.127 (18), p.2219-2230

2016

Volltextzugriff (PDF)

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924

Molecular cancer therapeutics, 2013-10, Vol.12 (10), p.1958-1967

2013

Volltextzugriff (PDF)

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

Investigational new drugs, 2015-06, Vol.33 (3), p.652-663

2015

Volltextzugriff (PDF)

Abstract 3719: TAK-243, a small molecule inhibitor of the ubiquitin activating enzyme (UAE), disrupts DNA damage repair and sensitizes tumor cells and xenografts to ionizing radiation

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3719-3719

2016

Volltextzugriff (PDF)

Regulation of T cell receptor complex-mediated signaling by ubiquitin and ubiquitin-like modifications

American journal of clinical and experimental immunology, 2014-01, Vol.3 (3), p.107-123

2014

Volltextzugriff (PDF)

Nedd8-Activating Enzyme Inhibition Enhances Anti-Tumor Immunity and PD1 Blockade in In Vivo lymphoma Models

Blood, 2021-11, Vol.138 (Supplement 1), p.2414-2414

2021

Volltextzugriff (PDF)

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma

Blood, 2010-09, Vol.116 (9), p.1515-1523

2010

Volltextzugriff (PDF)

The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models

Blood, 2021-11, Vol.138 (Supplement 1), p.2268-2268

2021

Volltextzugriff (PDF)

Insulin-Like Growth Factor-Binding Protein 3 Expression Increases during Immortalization of Cervical Keratinocytes by Human Papillomavirus Type 16 E6 and E7 Proteins

The American journal of pathology, 2002-08, Vol.161 (2), p.603-610

2002

Volltextzugriff (PDF)

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Blood, 2019-11, Vol.134 (Supplement_1), p.4313-4313

2019

Volltextzugriff (PDF)

Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS2667-TPS2667

2021

Volltextzugriff (PDF)

TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2698-TPS2698

2022

Volltextzugriff (PDF)

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Blood, 2019-11, Vol.134 (Supplement_1), p.1593-1593

2019

Volltextzugriff (PDF)

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Blood, 2021-11, Vol.138 (Supplement 1), p.2488-2488

2021

Volltextzugriff (PDF)

1 – 25 von 137

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(130)
Mit Volltextzugriff
(123)

Publikationsform

Sprache

Englisch
(137)

Erscheinungsjahr

n.n

Thema

Science & Technology
(78)
Life Sciences & Biomedicine
(65)
Humans
(48)
Female
(27)
Animals
(17)
Male
(17)
Oncology
(17)
Adult
(16)
Middle Aged
(15)
Mice
(14)
Aged
(13)
Tumors
(11)
Cancer
(10)
Mutation
(10)
Antineoplastic Agents - Pharmacology
(8)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Multidisciplinary Sciences
(8)
Science & Technology - Other Topics
(8)
Adolescent
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism

The discovery of a reciprocal relationship between tyrosine-kinase signaling and cullin neddylation

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

Cancer-Related Decision-Making Among Adolescents, Young Adults, Caregivers, and Oncology Providers

"Empathy without sympathy": An analysis of support-related preferences among young adult cancer survivors

T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

Abstract 3719: TAK-243, a small molecule inhibitor of the ubiquitin activating enzyme (UAE), disrupts DNA damage repair and sensitizes tumor cells and xenografts to ionizing radiation

Regulation of T cell receptor complex-mediated signaling by ubiquitin and ubiquitin-like modifications

Nedd8-Activating Enzyme Inhibition Enhances Anti-Tumor Immunity and PD1 Blockade in In Vivo lymphoma Models

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma

The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models

Insulin-Like Growth Factor-Binding Protein 3 Expression Increases during Immortalization of Cervical Keratinocytes by Human Papillomavirus Type 16 E6 and E7 Proteins

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies

TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Suchergebnisse filtern